UPDATE 2-Tocagen's brain cancer treatment fails late-stage study, shares crash
September 12, 2019 at 11:15 AM EDT
Tocagen Inc's shares fell nearly 80% after its experimental treatment failed to extend life of brain cancer patients in a study, the latest in a series of setbacks for patients awaiting new treatment options for the condition.
